Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
This paper presents a comprehensive study evaluating the efficacy and safety of psilocybin-assisted therapy in treating major depressive disorder (MDD) over a 12-month follow-up period, with 120 participants randomized into immediate and delayed treatment groups. The results demonstrated significant and sustained improvements in depressive symptoms, quality of life, anxiety, and functional outcomes, with a favorable safety profile, highlighting the potential of psilocybin-assisted therapy as a promising alternative treatment for MDD. However, some limitations, such as the lack of a placebo group and the relatively small sample size, warrant further research to establish optimal treatment protocols and investigate the generalizability of the findings.
by 
